Hemogenyx Pharmaceuticals Plc

OTCPK:HOPH.F Stock Report

Market Cap: US$69.7m

Hemogenyx Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

OTCPK:HOPH.F Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
29 Jul 25BuyUS$333,463Vladislav SandlerIndividual133,690US$2.49

Insider Trading Volume

Insider Buying: HOPH.F insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of HOPH.F?
Owner TypeNumber of SharesOwnership Percentage
Public Companies8,7000.162%
Private Companies49,6410.926%
Individual Insiders854,19115.9%
General Public896,63616.7%
Institutions3,552,09966.3%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 59.8%.


Top Shareholders

Top 25 shareholders own 82.5% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
19.3%
Hargreaves Lansdown Asset Management Ltd.
1,032,028US$13.4m12.2%0.03%
14.2%
Aberdeen Group Plc
759,977US$9.9m23.7%0.01%
9.55%
HBOS Investment Fund Managers Limited
512,082US$6.7m9.31%0.04%
8.74%
Barclays Bank PLC
468,676US$6.1m20.3%0.01%
7.84%
Vladislav Sandler
420,528US$5.5m-30.4%no data
7.78%
IG Group Holdings plc
417,200US$5.4m12.6%0.35%
4.33%
David Smith
231,948US$3.0m0%no data
3.5%
Alexis Sandler
187,726US$2.4m0%no data
2.87%
HSBC Global Asset Management (UK) Limited
153,779US$2.0m1.26%no data
0.53%
43North LLC
28,428US$369.7k0%no data
0.52%
Prevail Partners
27,666US$359.8k0%100.0%
0.47%
Raymond James Wealth Management Limited
25,103US$326.5k28.8%no data
0.32%
Equiniti Group Limited
16,997US$221.1k3.63%no data
0.32%
Fidelity International Ltd
16,946US$220.4k-19.1%no data
0.28%
Integrated Financial Arrangements plc
15,119US$196.6k24.4%0.01%
0.27%
GHC Property Services Limited
14,587US$189.7k0%no data
0.26%
Peter Redmond
13,989US$181.9k11%no data
0.26%
Copier Systems Limited
13,891US$180.7k0%no data
0.24%
James Brearley & Sons Ltd.
12,899US$167.8k-18.2%0.06%
0.23%
Canaccord Genuity Wealth (International) Ltd.
12,341US$160.5k0%no data
0.21%
UBS Asset Management AG
11,480US$149.3k-19.6%no data
0.18%
Merrill Lynch, Pierce, Fenner & Smith Incorporated
9,433US$122.7k0%no data
0.14%
eToro (UK) Ltd.
7,634US$99.3k6.07%0.06%
0.12%
GHC Capital Markets Ltd.
6,238US$81.1k0%0.19%
0.12%
Lloyds Banking Group plc
6,200US$80.6k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/20 01:25
End of Day Share Price 2025/07/23 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hemogenyx Pharmaceuticals Plc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.